video corpo

JULIET ® OL
2Pages

{{requestButtons}}

Catalog excerpts

JULIET ® OL - 1

JULIET®OL Study #52001 The JULIET®OL, lumbar intersomatic poly-ether-ether-ketone cage used for symptomatic degenerative disc diseases treatment by arthrodesis. Safety and effectiveness evaluation after two years follow-up Investigator initiated study FDA approved for this indication Region: France Status: Completed Post CE-Marking Follow-up Study submitted to HAS (FR) Primary Objectives:  Safety of JULIET®OL, lumbar inter-somatic cage, evaluation based on all events observed (controls, investigations, hospitalizations, interventions) during 2 year follow-up after arthrodesis.  Overall performance of JULIET®OL, evaluated at the end of 2 years follow-up period, as a composite primary endpoint, based on data at last visit: - Incidence and seriousness of implant related complications - Absence of lumbar and radicular pain - Absence of neurologic disorders (sensitive and/or motor) - Fusion status - Patient satisfaction - Global prognostic Secondary objectives: Early qualitative effectiveness evaluation, at 2 months after surgery for lumbar arthrodesis using JULIET®OL:  Overall success evaluated by Stauffer criteria: - Pain relief - Time after surgery for getting back to work - Diminution of physical activities - Pain medication  Functional improvement evaluated by Lassale criteria: - Claudication - Radicular pain (at rest and at effort) - Lumbar pain - Neurologic disorders - Pain medication - Kinesitherapy - Time after surgery for getting back to normal life  Radiologic criteria: - Implant positioning - Radicular compression Indication - condition: Symptomatic lumbar disc degenerative disease Study type: Observational, cohort, retrospective analysis Patients enrolled: 27 Primary outcomes: • Incidence of SAE and AE implant related • Absence of lumbar and radicular pain • Absence of neurologic disorders (sensitive and/or moto

Open the catalog to page 1
JULIET ® OL - 2

• Patient satisfaction • Global prognostic Secondary outcomes: • Changes in back and leg pain (compared to preoperative status) • Changes in physical activities capacity (compared to preoperative status) • Pain medication (drug's category and frequency) • Radicular pain (at rest and at effort) • Neurologic disorders (motor and/or sensitive) • Time after surgery for getting back to work • Time after surgery for getting back to normal life • Implant positioning • Radicular compression

Open the catalog to page 2

All Spineart catalogs and technical brochures

  1. JULIET®AN

    1 Pages

  2. JULIET® PO

    2 Pages

  3. BAGUERA ® C

    1 Pages